Table 3.
Funding sources.
| Study | Disease | Funding sources |
| Fargnoli et al [7] (2019) | ADa | None |
| Cork et al [8] (2019) | AD | Sanofi/Regeneron |
| Tsianakas et al [9] (2017) | AD | Sanofi/Regeneron |
| Tofte et al [10] (2018) | AD | Sanofi/Regeneron |
| Paller [11] (ongoing clinical trial) | AD | Not mentioned |
| Chang et al [12] (2016) | AD | National Taiwan University Hospital and the Yonghe Cardinal Tien Hospital |
| Harper et al [13] (2000) | AD | Novartis Pharmaceuticals |
| Silverberg et al [14] (2021) | AD | Pfizer |
| Lio et al [15] (2021) | AD | Eli Lilly and Company |
| Kawana et al [16] (2010) | AD | Not mentioned |
| Munday et al [17] (2002) | AD | Not mentioned |
| Ebata et al [18] (1997) | AD | Not mentioned |
| Savin et al [19] (1979) | AD | May and Baker Ltd |
| Parikh-Das et al [20] (2017) | AD | Johnson & Johnson |
| Ständer et al [21] (2016) | AD | Not mentioned |
| Kubota et al [22] (2009) | AD | None |
| Doss et al [23] (2009) | AD | Astellas Pharma Europe Limited |
| Leo et al [24] (2004) | AD | Not mentioned |
| Jaworek et al [25] (2020) | AD | Not mentioned |
| Pustišek et al [26] (2016) | AD | None |
| Bae et al [27] (2012) | AD | Korea Health 21 R&D Project |
| Deleuran et al [28] (2020) | Pruritus and xerosis | Pierre Fabre Dermo-Cosmetique |
| Rossi et al [29] (2016) | Pruritus and xerosis | Not mentioned |
| Chiricozzi et al [30] (2020) | Prurigo nodularis | None |
| Kontochristopoulos et al [31] (2016) | Psoriasis vulgaris | Leo Greece |
| Zuberbier et al [32] (2009) | Chronic idiopathic pruritus | Not mentioned |
aAD: atopic dermatitis.